Nagi Bioscience obtains the prestigious SERI-funded EIC Accelerator Grant to accelerate development and commercial scale-up of their unique Organism-on-Chip product.
Since 2019, Nagi Bioscience offers tailored testing services by screening active compounds and drugs on transgenic and mutant C. elegans strains of interest, an innovative and cost-effective method towards a new era of drug discovery. Nagi’s technology combining microfluidics and microscopic worms aims to challenge the current biological testing standards while reducing costs, delays and ethical impact of product development pipelines across several industrial segments.
Having completed to date multiple successful projects with different customers across the pharma, biotech, agrochemicals and CROs sectors, Nagi’s next milestone is to make their technology available to the market. With the €2.5 million granted, Nagi Bioscience will significantly accelerate the development of the commercial scale-up of its first generation of products for large-scale automated in vivo testing of drugs and chemicals on the biological model C. elegans.
“We are thrilled to see Nagi Bioscience among the grantees of what is probably the most selective Startup funding program at European level. This recognition confirms the relevance and added value of Nagi’s technology, acknowledges the fantastic work of our team and pushes Nagi one step further in its mission to transform the field of biological testing” said Matteo Cornaglia, Nagi’s CEO and co-founder.
Nagi’s Organism-on-Chip technology enables working with C. elegans, for the first time, in a fully automated and standardized way to provide drug and chemical discovery with in vivo biological data at unprecedented speed, cost effectiveness, and confidence.
Chris Radloff, Board Director and Angel Investor at Nagi Bioscience, adds: “Winning the EIC Accelerator Grant is certainly a testimony to the attractiveness of Nagi’s innovations. The Grant will help Nagi Bioscience to further boost product industrialization and making the technology available to a broader group of toxicology testing laboratories and biopharma companies”.
Professing the transition to the new era of biological testing as their vision, being selected by the EIC accelerator program is going to be crucial to make Nagi’s vision a reality.